Glycemic Control With Insulin Glargine Plus Insulin Glulisine Versus Premixed Insulin Analogues in Real-World Practices: A Cost-Effectiveness Study With a Randomized Pragmatic Trial Design

Clinical Therapeutics

Volumn 33, Issue 7, 2011, Pages 841-850

  Levin, Philip A ^a   Zhang, Quanwu ^b   Mersey, James H ^a   Lee, Francis Y ^a   Bromberger, Lee A ^a   Bhushan, Madhu ^c   Bhushan, Rajat ^c  

^a MODEL Clinical Research   (United States)

^b SANOFI   (France)

^c Metabolic Center of Louisiana Research Foundation   (United States)

Author keywords

Cost effectiveness; Insulin glargine; Insulin glulisine; Premixed insulin; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BODY WEIGHT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BLOOD GLUCOSE; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 79960245792     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.05.091     Document Type: Article

References (43)

1. Janka H.U., Plewe G., Riddle M.C., et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005, 28:254-259.
2. Janka H.U., Högy B. Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial. Eur J Health Econ 2008, 9:165-170.
3. Raskin P., Allen E., Hollander P., et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005, 28:260-265.
4. Ray J.A., Valentine W.J., Roze S., et al. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US. Diabetes Obes Metab 2007, 9:103-113.
5. Qayyum R., Bolen S., Maruthur N., et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 2008, 149:549-559.
6. Ilag L.L., Kerr L., Malone J.K., Tan M.H. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther 2007, 29:1254-1270.
7. Sun P., Wang R., Jacober S. The effectiveness of insulin initiation regimens in patients with type 2 diabetes mellitus: a large national medical records review study comparing a basal insulin analogue to premixed insulin. Curr Med Res Opin 2007, 23:3017-3023.
8. Robbins D.C., Beisswenger P.J., Ceriello A., et al. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2007, 29:2349-2364.
9. Tamemoto H., Ikoma A., Saitoh T., et al. Comparison of once-daily glargine plus sulfonylurea with twice-daily 70/30 aspart premix in insulin-naive Japanese patients with diabetes. Diabetes Technol Ther 2007, 9:246-253.
10. Halbron M., Jacqueminet S., Sachon C., et al. Insulin therapy for type 2 diabetes: premixed or basal-prandial?. Diabetes Metab 2007, 33:316-320.
11. Jang H.C., Guler S., Shestakova M. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help?. Results from a subanalysis of the PRESENT study. Int J Clin Pract 2008, 62:1013-1018.
12. Gumprecht J., Benroubi M., Borzi V., et al. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study. Int J Clin Pract 2009, 63:966-972.
13. Fonseca V., Davidson J., Home P., et al. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. Curr Med Res Opin 2010, 26:1621-1628.
14. Houlden R., Ross S., Harris S., et al. Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of type 2 diabetes: the Canadian INSIGHT Study. Diabetes Res Clin Pract 2007, 78:254-258.
15. Masuda H., Sakamoto M., Irie J., et al. Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naive type 2 diabetic patients. Diabetes Obes Metab 2008, 10:1261-1265.
16. Godwin M., Ruhland L., Casson I., et al. Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. BMC Med Res Methodol 2003, 3:28.
17. Macpherson H. Pragmatic clinical trials. Complement Ther Med 2004, 12:136-140.
18. Brass E.P. The gap between clinical trials and clinical practice: the use of pragmatic clinical trials to inform regulatory decision making. Clin Pharmacol Ther 2010, 87:351-355.
19. Pragmatic Clinical Trials. Center for Medical Technology Policy 2008, Accessed May 10, 2011. http://www.cmtpnet.org/comparative-effectiveness/pragmatic-trials.
20. Thorpe K.E., Zwarenstein M., Oxman A.D., et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 2009, 62:464-475.
21. Karanicolas P.J., Montori V.M., Devereaux P.J., et al. A new "mechanistic-practical" framework for designing and interpreting randomized trials. J Clin Epidemiol 2009, 62:479-484.
22. Oxman A.D., Lombard C., Treweek S., et al. Why we will remain pragmatists: four problems with the impractical mechanistic framework and a better solution. J Clin Epidemiol 2009, 62:485-488.
23. Schwartz D., Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 1967, 20:637-648.
24. Ware J.H., Hamel M.B. Pragmatic trials-guides to better patient care?. N Engl J Med 2011, 364:1685-1687.
25. Reliability and validity of a diabetes quality-of-life measure for the diabetes control and complications trial (DCCT). The DCCT Research Group. Diabetes Care 1988, 11:725-732.
26. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990, 16:199-208.
27. Reilly M.C., Zbrozek A.S., Dukes E.M. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993, 4:353-365.
28. Garratt A.M., Schmidt L., Fitzpatrick R. Patient-assessed health outcome measures for diabetes: a structured review. Diabet Med 2002, 19:1-11.
29. Burroughs T.E., Desikan R., Waterman B.M., et al. Development and validation of the Diabetes Quality of Life Brief Clinical Inventory. Diabetes Spectrum 2004, 17:41-49.
30. Cameron C.G., Bennett H.A. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ 2009, 180:400-407.
31. Raccah D., Bretzel R.G., Owens D., Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough-what next?. Diabetes Metab Res Rev 2007, 23:257-264.
32. Nathan D.M., Buse J.B., Davidson M.B., et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006, 29:1963-1972.
33. Chan Y.H. Randomised controlled trials (RCTs)-sample size: the magic number?. Singapore Med J 2003, 44:172-174.
34. Bretzel R.G., Nuber U., Landgraf W., et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008, 371:1073-1084.
35. Le Floch J.P., Levy M., Mosnier-Pudar H., et al. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabetes Care 2009, 32:32-37.
36. Riddle M.C., Rosenstock J., Gerich J. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003, 26:3080-3086. Insulin Glargine 4002 Study Investigators.
37. Davies M., Storms F., Shutler S., et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005, 28:1282-1288.
38. Lankisch M.R., Ferlinz K.C., Leahy J.L., Scherbaum W.A. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 2008, 10:1178-1185.
39. Rosenblum M.S., Kane M.P. Analysis of cost and utilization of health care services before and after initiation of insulin therapy in patients with type 2 diabetes mellitus. J Manag Care Pharm 2003, 9:309-316.
40. Schwartz S., Sievers R., Strange P., et al. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 2003, 26:2238-2243.
41. Rhoads G.G., Orsini L.S., Crown W., et al. Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes. J Occup Environ Med 2005, 47:447-452.
42. Bullano M.F., Al-Zakwani I.S., Fisher M.D., et al. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin 2005, 21:291-298.
43. Bullano M.F., Fisher M.D., Grochulski W.D., et al. Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products. Am J Health Syst Pharm 2006, 63:2473-2482.